Incisive Genetics develops a non-viral delivery platform for genetic therapies that enables one-step encapsulation of active CRISPR components within lipid nanoparticles. The company’s pre-clinical pipeline includes programs targeting neurologic and ocular genetic diseases. Led by Dr. Blair R. Leavitt and established in 2018, the firm is focused on advancing its delivery technology and expanding its intellectual property. Incisive intends to use new funding to develop its manufacturing process and capabilities and to advance key studies to enhance its gene editing delivery platform. The company is in the pre-clinical stage and is using seed financing to support technology and manufacturing development.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2021